Literature DB >> 2939101

Evaluation of teicoplanin and vancomycin disk susceptibility tests.

A L Barry, C Thornsberry, R N Jones.   

Abstract

Disk tests with two glycopeptide antibiotics, teicoplanin and vancomycin, were evaluated, and MICs were compared with those of fusidic acid and coumermycin. For tests with 30-micrograms vancomycin disks, we recommend modification of the current zone size standards to less than or equal to 10 mm for resistant and greater than or equal 15 mm for susceptible. For teicoplanin disk tests, 30-micrograms disks are recommended, with zone size interpretive standards of less than or equal to 10 and greater than or equal 14 mm. Since no resistant clinical isolates are available at this time, susceptibility testing of either drug is rarely necessary, and zone size standards are tentative.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2939101      PMCID: PMC268579          DOI: 10.1128/jcm.23.1.100-103.1986

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  9 in total

1.  Teicoplanin, a new antibiotic from Actinoplanes teichomyceticus nov. sp.

Authors:  S Somma; L Gastaldo; A Corti
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

2.  Teicoplanin.

Authors:  A H Williams; R N Grüneberg
Journal:  J Antimicrob Chemother       Date:  1984-11       Impact factor: 5.790

3.  In vitro activity and human pharmacokinetics of teicoplanin.

Authors:  L Verbist; B Tjandramaga; B Hendrickx; A Van Hecken; P Van Melle; R Verbesselt; J Verhaegen; P J De Schepper
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

4.  In vitro activities of teichomycin, fusidic acid, flucloxacillin, fosfomycin, and vancomycin against methicillin-resistant Staphylococcus aureus.

Authors:  S H Guenthner; R P Wenzel
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

5.  Teichomycins, new antibiotics from Actinoplanes teichomyceticus nov. sp. IV. Separation and characterization of the components of teichomycin (teicoplanin).

Authors:  A Borghi; C Coronelli; L Faniuolo; G Allievi; R Pallanza; G G Gallo
Journal:  J Antibiot (Tokyo)       Date:  1984-06       Impact factor: 2.649

6.  In vitro activity of teichomycin A 2 in comparison with penicillin and vancomycin against gram-positive cocci.

Authors:  A Bauernfeind; C Petermüller
Journal:  Eur J Clin Microbiol       Date:  1982-10       Impact factor: 3.267

7.  In vitro activity of teichomycin compared with those of other antibiotics.

Authors:  H C Neu; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

8.  Comparative in vitro activities of teichomycin and other antibiotics against JK diphtheroids.

Authors:  L Jadeja; V Fainstein; B LeBlanc; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

9.  Teichomycin: in-vitro and in-vivo evaluation in comparison with other antibiotics.

Authors:  R Pallanza; M Berti; B P Goldstein; E Mapelli; E Randisi; R Scotti; V Arioli
Journal:  J Antimicrob Chemother       Date:  1983-05       Impact factor: 5.790

  9 in total
  18 in total

1.  Methicillin-resistant Staphylococcus aureus in Zimbabwe.

Authors:  Kathrine Mauchaza; Farai D Madzimbamuto; Seymour Waner
Journal:  Ghana Med J       Date:  2016-06

2.  Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicemia who recovered after administration of vancomycin.

Authors:  F Brunet; G Vedel; F Dreyfus; J F Vaxelaire; T Giraud; B Schremmer; J F Monsallier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-02       Impact factor: 3.267

3.  Clinical efficacy of teicoplanin.

Authors:  P Calain; F Waldvogel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-02       Impact factor: 3.267

4.  Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations.

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

5.  Problems with the disk diffusion test for detection of vancomycin resistance in enterococci.

Authors:  J M Swenson; B C Hill; C Thornsberry
Journal:  J Clin Microbiol       Date:  1989-09       Impact factor: 5.948

6.  High-level vancomycin-resistant enterococci causing hospital infections.

Authors:  A H Uttley; R C George; J Naidoo; N Woodford; A P Johnson; C H Collins; D Morrison; A J Gilfillan; L E Fitch; J Heptonstall
Journal:  Epidemiol Infect       Date:  1989-08       Impact factor: 2.451

7.  In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis.

Authors:  D F Sahm; J Kissinger; M S Gilmore; P R Murray; R Mulder; J Solliday; B Clarke
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

8.  Low-level vancomycin resistance in Clostridium innocuum.

Authors:  F Mory; A Lozniewski; V David; J P Carlier; L Dubreuil; R Leclercq
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

9.  New vancomycin disk diffusion breakpoints for enterococci. The National Committee for Clinical Laboratory Standards Working Group on Enterococci.

Authors:  J M Swenson; M J Ferraro; D F Sahm; P Charache; F C Tenover
Journal:  J Clin Microbiol       Date:  1992-10       Impact factor: 5.948

10.  Quality control limits for teicoplanin susceptibility tests and confirmation of disk diffusion interpretive criteria.

Authors:  A L Barry; R N Jones; T L Gavan; C Thornsberry
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.